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Introduction: Intravenous (IV) voriconazole is not recommended in patients with creatinine clearance <50 ml/min
to avoid potentially toxic accumulation of sulfobutylether-β-cyclodextrin (SBECD). The purpose of this study was to
evaluate the pharmacokinetics of SBECD, voriconazole, and voriconazole N-oxide in critically ill patients undergoing
continuous renal replacement therapy (CRRT) and to determine if CRRT removes SBECD sufficiently to allow for the
use of IV voriconazole without significant risk of SBECD accumulation.
Methods: This prospective, open-label pharmacokinetic study enrolled patients >18 years old receiving IV voriconazole
for a known or suspected invasive fungal infection while undergoing CRRT. Serial blood and effluent samples were
collected on days 1, 3, 5, 7, and every 3 to 5 days thereafter. SBECD, voriconazole, and voriconazole N-oxide plasma
and effluent concentrations were measured by liquid chromatography-tandem mass spectrometry. Pharmacokinetic,
pharmacodynamic, and pharmacogenetic analyses were conducted.
Results: Ten patients (mean ± standard deviation (SD)) 53 ± 11 years old, 50% male, 81 ± 14 kg, with Acute Physiologic
and Chronic Health Evaluation II (APACHE II) scores of 31.5 ± 3.8 were evaluated. All patients underwent continuous
venovenous hemofiltration (CVVH) with a median predilution replacement fluid rate of 36 (interquartile range (IQR)
32 to 37) ml/kg/hr and total ultrafiltration rate of 38 (IQR 34 to 39) ml/kg/hr. Mean ± SD voriconazole and SBECD
dosages administered were 8.1 ± 2.1 mg/kg/day and 129 ± 33 mg/kg/day, respectively. Voriconazole plasma trough
concentrations were >1 mg/L in all patients with CVVH accounting for only 15% of the total body clearance. CVVH
accounted for 86% of the total body clearance of SBECD with the majority of the dose being recovered in the effluent.
Minimal increases in dose normalized SBECD area under the concentration-time curve from 0 to 12 hours (AUC0-12)
(4,484 ± 4,368 to 4,553 ± 2,880 mg*hr/L; P = 0.97) were observed after study day 1.
Conclusions: CVVH effectively removed SBECD at a rate similar to the ultrafiltration rate. Voriconazole clearance by
CVVH was not clinically significant. Standard dosages of IV voriconazole can be utilized in patients undergoing CVVH
without significant risk of SBECD accumulation.
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Voriconazole is a triazole antifungal that has a broad
spectrum of activity against yeast, molds, and dimorphic
fungi. Voriconazole is currently recommended as the
first-line therapy for patients with invasive Aspergillus
infection and can also be utilized to treat patients with
other life-threatening systemic mycoses [1,2]. Since
voriconazole has limited water solubility, the intra-
venous (IV) voriconazole formulation includes the ve-
hicle sulfobutylether-beta-cyclodextrin sodium (SBECD).
SBECD is comprised of a multitude of polymeric struc-
tures with varying degrees of substitution. SBECD has a
molecular mass of approximately 2,163 Da, is not protein
bound, has a volume of distribution (Vd) similar to extra-
cellular water (0.2 L/kg), and is predominately excreted
by glomerular filtration in the kidney [3,4]. In patients
with normal renal function, SBECD is effectively elimi-
nated with a half-life of less than 2 hours, but accumula-
tion of SBECD is known to occur in patients with a
creatinine clearance (CrCl) <50 ml/min [5]. Accumula-
tion of SBECD in animals at doses 50-fold greater
(3,000 mg/kg) than typically administered in humans has
been associated with liver necrosis and obstruction of the
renal tubules [3]. These toxicities have not yet been ob-
served in humans; however, it is recommended that oral
voriconazole be utilized instead of IV voriconazole in pa-
tients with a CrCl <50 ml/min [5]. Therefore, clinicians
must either face the potential risk of SBECD accumula-
tion or choose an alternative antifungal therapy in these
patients.
Patients with severe systemic fungal infections are
commonly treated in the intensive care unit (ICU).
These patients frequently have complicated comorbidi-
ties including bone marrow or solid organ transplant,
acute kidney injury, multiorgan dysfunction, and shock.
Unfortunately, absorption of enterally administered anti-
microbials can be erratic, leading to inadequate plasma
concentrations and treatment failure in some patients
[6-14]. Many ICU patients also have relative contraindi-
cations to taking oral medications, including gastro-
intestinal bleeding, mucositis, inadequate oral access,
nonfunctioning gastrointestinal (GI) tract, or gastroparesis.
Therefore, many clinicians prefer to administer voricona-
zole intravenously in these patients.
In addition, many critically ill patients with acute kid-
ney injury are hypotensive and cannot tolerate the blood
flow rates or fluid shifts that occur with intermittent dia-
lysis therapy. Therefore, critically ill patients commonly
receive continuous renal replacement therapy (CRRT).
This mode is highly effective at removing fluid and sol-
ute from blood. It is known that SBECD is removed by
intermittent hemodialysis at a rate similar to a CrCl
of 55 ml/min, and that accumulation of SBECD occurs
only during the time periods when dialysis is not beingprovided to the patient [4,15]. Thus, it is plausible that
CRRT would be effective at removing SBECD, thereby
allowing for the safe administration of IV voriconazole
to these critically ill patients. Therefore, the primary ob-
jective of this study was to determine if CRRT can ad-
equately remove the SBECD vehicle from the plasma so
that IV voriconazole may be utilized in critically ill pa-
tients with renal dysfunction. Secondarily, the pharma-
cokinetics of IV voriconazole and its N-oxide metabolite,
influences of cytochrome P450 (CYP) 2C19 phenotype
on voriconazole and its N-oxide metabolite pharmaco-




This study was an open-label, single-center, descrip-
tive pharmacokinetic evaluation at the University of
Colorado Hospital. The decision to administer IV vorico-
nazole was made by the attending physician and was not
dictated by the study. From May 2010 to December 2012,
patients >18 years of age who were receiving CRRT and
were prescribed IV voriconazole therapy for the treat-
ment of a fungal infection were considered eligible for
study participation. Patients expected to be on CRRT or
intravenous voriconazole therapy for less than 5 days
were excluded.
This study was approved by the Colorado Multiple
Institutional Review Board. Informed consent and health
insurance portability and accountability act authorization
was obtained from the patient’s designated proxy prior to
enrollment.
Continuous renal replacement therapy
All patients underwent CRRT utilizing the NxStage™
System One dialysis machine (NxStage Medical Inc.
Lawrence, MA, USA) with NxStage Cartridge Express
and filter (high-flux polyethersulfone membrane with
1.5 m2 membrane surface area). Continuous venovenous
hemofiltration (CVVH) was the mode utilized in all pa-
tients. Blood flow rates ranged from 200 to 300 ml/min
and predilution replacement therapy fluid flow rates
were between 2,000 and 6,000 ml/hr. Dialysis initiation,
settings, and net ultrafiltration were prescribed by the con-
sulting nephrology service. CRRT was performed without
the use of citrate anticoagulation.
Voriconazole administration and sample collection
Patients were started on voriconazole per routine stand-
ard of care at a loading dose of 6 mg/kg IV every
12 hours x 2 doses, then 4 mg/kg IV every 12 hours
thereafter. Voriconazole maintenance doses could be re-
duced by 50% in patients with Child Pugh A or B hep-
atic disease per package insert recommendations.
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netic sampling for determination of SBECD, voricona-
zole, and voriconazole N-oxide concentrations. Plasma
and effluent samples were collected at 0, 0.5, 1, 2, 3, 4, 6,
8, and 12 hours. If the patient remained on CVVH at
day 7, plasma and dialysate samples were collected at
time 0, 2, and 8 hours on that day. Thereafter, sparse
sampling occurred every 3 to 5 days. Blood samples were
immediately centrifuged at 3,000 g and plasma and efflu-
ent samples were stored at −80°C until analysis.
Quantification of SBECD, voriconazole, and voriconazole
N-oxide concentrations
SBECD, voriconazole, and voriconazole N-oxide concentra-
tions were determined utilizing a liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method at
the University of Colorado Anschutz Medical Campus
Medicinal Chemistry Core Facility (detailed methodology
can be found in Additional file 1).
Pharmacokinetic analysis
Plasma and dialysate concentration-time data for SBECD,
voriconazole, and voriconazole N-oxide were ana-
lyzed by standard noncompartmental pharmacokinetics
(pharmacokinetic analysis methodology described in
detail in Additional file 1). All calculations were
made by programming pharmacokinetic equations into
Microsoft Excel 2010 (Microsoft Corporation, Redmond,
WA, USA) and were validated using WinNonlin version
5.0.1 (Pharsight Corporation, Mountain View, CA, USA).
To evaluate drug accumulation, dose-normalized area
under the concentration-time curve (AUC), maximum
drug concentration in the plasma (Cmax), and minimum
drug concentration in the plasma (Cmin) were evaluated
on study day 1 versus study days ≥3 and compared with a
paired t test.
Pharmacokinetic modeling
The pharmacokinetic parameters total systemic clear-
ance (CLs) and Vd were calculated for SBECD using
population pharmacokinetic techniques in ADAPT V
software (Biomedical Simulation Resource, Los Angeles,
CA, USA). Pharmacokinetic parameters were calculated
for the entire population and for the various levels of
CVVH ultrafiltration (2,000, 3,000, and 6,000 ml/hr),
using a one-compartment, short infusion model. The
population pharmacokinetic parameters and associated
error were then utilized to simulate expected concentra-
tions for the various levels of CVVH in ADAPT V, using
the individual simulation with output error option se-
lected. The dose used for simulation represented a
typical administration of SBECD (96 mg/kg IV every
12 hours for two doses, followed by 64 mg/kg IV every
12 hours) for an 80 kg individual, with a one-hourinfusion length. Concentrations were simulated every
hour, starting at first dose and continuing through steady
state. Data from these simulations were then plotted
using GraphPad Prism Software (version 5.04, La Jolla,
CA, USA).
Monte Carlo simulations for probability of target
attainment
Monte Carlo simulation (Crystal Ball version 7, Oracle
Corporation, Redwood Shores, CA, USA) was used to
calculate probability of target attainment (PTA) for phar-
macodynamic goals. The model randomly applied values
for CLs, Vd, weight, and unbound (42% unbound (range
36 to 48%)) voriconazole AUC0 to 12 (fAUC0-12) derived
from data obtained from the study patients. Minimum
inhibitory concentration (MIC) distributions obtained from
the Clinical and Laboratory Standards Institute (CLSI),
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST), or provided by Pfizer pharmaceuticals
were placed into our Monte Carlo simulation for compari-
son to voriconazole plasma concentrations and pharmaco-
kinetic variability (isolate numbers and MIC distributions
by database can be found in Table S1 in Additional file 1).
Five thousand simulations were performed at each MIC
value and for each of the selected pathogens. The probabil-
ity of target attainment for Candida albicans, C. glabrata,
C. krusei, C. parapsilosis, C. tropicalis, Aspergillus fumiga-
tus, A. niger, and A. terreus were evaluated for a goal
fAUC/MIC >25 or >35 at a voriconazole loading dose of
6 mg/kg IV every 12 hours and maintenance dosages of 4
and 6 mg/kg every 12 hours. If >90% target obtainment
was not observed, continued analyses of loading and main-
tenance doses of 8 mg/kg, 10 mg/kg, and 12 mg/kg every
12 hours were conducted.
Cytochrome P450 (CYP) 2C19 pharmacogenetic analysis
Genetic polymorphisms in CYP2C19, the principal enzyme
that metabolizes voriconazole, were interrogated in all
study patients. Specifically, CYP2C19*2 (loss-of-function),
CYP2C19*3 (loss-of-function), and CYP2C19*17 (gain-of-
function) polymorphisms were genotyped using PCR-
pyrosequencing (pharmacogenetic for consistency analysis
described in more detail within Additional file 1). CYP2C19
metabolizing enzyme phenotypes (that is, ultrarapid, ex-
tensive, intermediate, or poor metabolizers) were assigned
based on genotypes using literature conventions [16].
Safety end point and adverse effect monitoring
Patients were assessed for potential adverse effects asso-
ciated with SBECD accumulation, with a focus on renal
and hepatic function tests as these toxicities have been
demonstrated in animal studies. Serum creatinine (SCr)
values were monitored and worsening or reversal of renal
dysfunction was assessed in each patient during and after
Table 1 Patient characteristics
Age (years) Weight (kg) Sex Race APACHE II SOFA Voriconazole indication
Mean ± SD 53 ± 11 81 ± 14 50% Male 70% White 32 ± 4 16 ± 4 Pulmonary aspergillosis (n = 4)
10% Asian Empiric broad spectrum antifungal (n = 4)
Median (range) 55 (33–70) 83 (54–100) 10% Hispanic/White 31 (27–38) 17 (9–20) Scedosporium brain abscess (n = 1)
10% Native American Candida glabrata peritonitis (n = 1)
Data are presented as mean ± standard deviation (SD); median (minimum to maximum range); or numbers/proportions. APACHE II, Acute Physiologic and Chronic
Health Evaluation II score; SOFA, Sequential Organ Failure Assessment score.
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evaluated by assessment of SCr values and the need for
continued intermittent hemodialysis therapy after ICU and
hospital discharge. To assess hepatic function, alterations
in aspartate aminotransferase, alanine aminotransferase,
total bilirubin, albumin, total protein, and international
normalized ratio were evaluated in each patient.
Results
Ten patients were enrolled. Patients were (mean ± standard
deviation (SD)) 53 ± 11 years old, 50% male, 81 ± 14 kg,
and had Acute Physiologic and Chronic Health Evaluation
II score (APACHE II) scores of 31.5 ± 3.8. Patient demo-
graphics are reported in Table 1 and patient classification
based upon CYP2C19 genotypes and phenotypes are
presented in Table 2. All enrolled patients were critic-
ally ill with multiple comorbidities and were receiving
IV voriconazole for the treatment of a known or sus-
pected systemic fungal infection. All patients received
CVVH with a median predilution replacement fluid rate
of 36 (IQR 32 to 37) ml/kg/hr and ultrafiltration rate of 38
(IQR 34 to 39) ml/kg/hr. Patients had minimal residual
renal function and remained anuric or oliguric during the
entire study period. Mean ± SD voriconazole and SBECD
dosages administered were 8.1 ± 2.1 mg/kg/day and 129 ±
33 mg/kg/day. Patients were enrolled in the study for a
mean of 5 ± 3 days (range 2 to 11 days).Table 2 Patient genotype and phenotype
Patient CYP2C19 genotype CYP2C19 phenotype assignment
1 *1/*1 Extensive metabolizer
2 *1/*17 Ultrarapid metabolizer
3 *1/*1 Extensive metabolizer
4 *1/*1 Extensive metabolizer
5 *1/*2 Intermediate metabolizer
6 *1/*1 Extensive metabolizer
7 *1/*1 Extensive metabolizer
8 *2/*17 Intermediate metabolizer
9 *1/*1 Extensive metabolizer
10 *1/*2 Intermediate metabolizer
An asterisk (*) followed by a numeral represents each allele in the given
genotype. CYP2C19, cytochrome P450 2C19 enzyme.A summary of the major SBECD pharmacokinetic var-
iables can be found in Table 3. SBECD was readily re-
moved by CVVH with a median sieving coefficient of
0.85 (IQR 0.52 to 1.1). CVVH accounted for 86% of
the total SBECD clearance, and 85% of the SBECD ad-
ministered was recovered in the effluent fluid. Minimal
SBECD plasma accumulation was observed, as demon-
strated by nonsignificant changes in dose-normalized
SBECD Cmax (703 ± 600 to 684 ± 432 mg/L; P = 0.94),
Cmin (228 ± 250 to 221 ± 189 mg/L; P = 0.94), and AUC0-
12 (4,484 ± 4,368 to 4,553 ± 2,880 mg*hr/L; P = 0.97) on
study day 1 versus days ≥3, respectively. Simulated SBECD
plasma concentration versus time curves on days 1 to 7 in
all patients and delineated by CVVH ultrafiltration rates of
2,000, 3,000, or 6,000 ml/hr are depicted in Figures 1, 2, 3
and 4 and Figure S1 in Additional file 2. The mean SBECD
clearance ranged from 1.75 L/hr at an ultrafiltration rate
of 2,000 ml/hr to 4.69 L/hr at an ultrafiltration rate of
6,000 ml/hr.
Voriconazole pharmacokinetic variables are presented
in Table 3. The voriconazole half-life (T1/2) was similar
amongst intermediate, extensive, and ultrarapid metabo-
lizers (18.3 hrs vs. 19.9 hrs vs. 21.4 hrs, respectively;
P = 0.86). No patients had the poor metabolizer phenotype.
The median fraction of voriconazole clearance attributable
to CVVH was 15% (IQR 12 to 21%). The median amount
of voriconazole recovered in the effluent fluid was 14%
(IQR 11 to 19%) and closely corresponded to the fraction
of voriconazole clearance due to CVVH.
The median (IQR) voriconazole N-oxide metabolite
Cmax, AUC0-12, voriconazole/voriconazole N-Oxide
AUC0-12 and Cmax ratios were 0.9 mg/L (0.4 to
1.5 mg/L), 11.9 mg*hr/L (5.0 to 20.7 mg*hr/L), 2.8 (2
to 4.6), and 3.6 (2.6 to 11.1), respectively. Mean plasma
voriconazole N-oxide Cmax, AUC0-12, voriconazole/
voriconazole N-oxide AUC0-12 and Cmax ratios were
similar among intermediate (1.4 mg/L, 13.9 mg*hr/L,
2.6, and 2.9), extensive (1.3 mg/L, 16.4 mg*hr/L, 6.3,
and 8.5), and ultrarapid metabolizers (0.9 mg/L,
10.3 mg*hr/L, 3.0, and 4.0). Voriconazole N-oxide was
readily removed by CVVH with a mean ± SD sieving
coefficient of 0.8 ± 0.2.
IV voriconazole at standard dosages produced steady-
state voriconazole plasma trough values >1 mg/L for
Table 3 Steady-state plasma pharmacokinetics of SBECD and voriconazole during CVVH
SBECD
Cmax (mg/L) Cmin (mg/L) T1/2 (hrs) AUC0-12 (mg*hr/L) Cls (L/hr/kg) Vd (L/kg) CVVH CL (L/hr/kg)
Mean 687.0 214.5 6.3 4396 0.03 0.3 0.02
SD 500.4 202.6 1.6 3325 0.02 0.2 0.01
Median 561.1 165.2 6.2 3621 0.02 0.2 0.01
25% 216.2 38.7 5.3 1352 0.01 0.1 0.01
75% 1102.4 305.8 7.3 6804 0.05 0.4 0.02
Voriconazole
Cmax (mg/L) Cmin (mg/L) T1/2 (hrs) AUC0-12 (mg*hr/L) Cls (L/hr/kg) Vd (L/kg) CVVH CL (L/hr/kg)
Mean 4.1 2.4 19.5 37 0.13 3.2 0.02
SD 1.4 1.1 10.7 14 0.06 1.5 0.02
Median 4.1 2.3 19.0 38 0.12 2.7 0.02
25% 3.3 2.0 13.1 30 0.09 2.1 0.01
75% 5.1 3.0 22.5 41 0.14 3.7 0.02
SBECD, sulfobutylether-β-cyclodextrin; CVVH, continuous venovenous hemofiltration; Cmax, maximum drug concentration in the plasma; Cmin, minimum drug
concentration in the plasma; T1/2, half-life; AUC0-12 area under the concentration-time curve from time 0 to 12 hours; Cls, total systemic clearance; Vd, volume of
distribution; CVVH CL clearance by continuous venovenous hemofiltration; SD, standard deviation.
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with a maintenance dose of 4 mg/kg every 12 hours was
>90% for A. fumigatus and all Candida species except C.
glabrata (Table 4). Maintenance voriconazole doses of
6 mg/kg every 12 hours were required to achieve >80%
target attainment for A. niger and A. terreus.
Patient outcomes were generally consistent with their
severity of disease. Six out of ten patients died prior to
hospital discharge. Of the four survivors, three patients
did not require chronic hemodialysis. No evidence of hep-
atic or renal disease attributable to SBECD was observed.Figure 1 Simulated plasma SBECD pharmacokinetic profiles in
all subjects. Data represent 1,000 patient simulations for SBECD
exposure with voriconazole 6 mg/kg IV every 12 hours for two
doses followed by 4 mg/kg IV every 12 hours from time 0 to day 7.
Data presented as mean concentration (solid line) and standard
deviation (dashed lines). SBECD, sulfobutylether-β-cyclodextrin;
IV, intravenous.Discussion
Our study demonstrates that SBECD is readily removed
by CVVH allowing for the use of IV voriconazole with-
out significant SBECD accumulation. CVVH was re-
sponsible for greater than 86% of the total systemic
SBECD clearance and this corresponded to a similar rate
of SBECD recovery in the effluent fluid. The finding that
SBECD is removed by extracorporeal filters is similar to
previous studies of intermittent hemodialysis modalities
[4,15,17]. An evaluation of four patients receiving IVFigure 2 Simulated plasma SBECD pharmacokinetic profiles in
subjects undergoing CVVH with an ultrafiltration rate of
2,000 ml/hr. Data represent 1,000 patient simulations for SBECD
exposure with voriconazole 6 mg/kg IV every 12 hours for two
doses followed by 4 mg/kg IV every 12 hours from time 0 to day 7.
Data presented as mean concentration (solid line) and standard
deviation (dashed lines). SBECD, sulfobutylether-β-cyclodextrin; CVVH,
continuous venovenous hemofiltration; IV, intravenous.
Figure 3 Simulated plasma SBECD pharmacokinetic profiles in
subjects undergoing CVVH with an ultrafiltration rate of
3,000 ml/hr. Data represent 1,000 patient simulations for SBECD
exposure with voriconazole 6 mg/kg IV every 12 hours for two
doses followed by 4 mg/kg IV every 12 hours from time 0 to day 7.
Data presented as mean concentration (solid line) and standard
deviation (dashed lines). SBECD, sulfobutylether-β-cyclodextrin; CVVH,
continuous venovenous hemofiltration; IV, intravenous.
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strated that SBECD can be effectively removed by dialy-
sis. Unfortunately, SBECD still accumulated between
dialysis sessions and SBECD trough concentrations
were >400 mcg/ml in three of the four patients by
days 10 to 13 of therapy [15]. In a more recent study
of 15 patients with end-stage renal disease undergoing
a 6-hour treatment with Genius dialysis, standardFigure 4 Simulated plasma SBECD pharmacokinetic profiles in
subjects undergoing CVVH with an ultrafiltration rate of
6,000 ml/hr. Data represent 1,000 patient simulations for SBECD
exposure with voriconazole 6 mg/kg IV every 12 hours for two
doses followed by 4 mg/kg IV every 12 hours from time 0 to day 7.
Data presented as mean concentration (solid line) and standard
deviation (dashed lines). SBECD, sulfobutylether-β-cyclodextrin; CVVH,
continuous venovenous hemofiltration; IV, intravenous.hemodialysis, or hemodiafiltration, it was found that all
three modalities were effective at removing SBECD with
approximately two-thirds of the administered dose being
recovered in the effluent. However, pharmacokinetic simu-
lations after repeated doses demonstrated that even if
intermittent hemodialysis with high-flux filter membranes
was conducted every 24 to 48 hours, SBECD exposure
would still be 6- to 7-fold higher than in patients with nor-
mal renal function [17]. Unlike these intermittent modal-
ities that allow for drug accumulation between dialysis
sessions, the use of CVVH in our study prevented further
accumulation of SBECD.
Overall, plasma SBECD exposure was higher than in
previous studies of healthy volunteers with a mean
Cmax of 687 mg/L vs. 458 mg/L and AUC0-12 of 4396
vs. 919 mg*hr/L, respectively [3]. CVVH resulted in a
mean SBECD terminal T1/2 of 7 hours, which is pro-
longed compared to healthy patients with an average
glomerular filtration rate of 120 ml/min (healthy subject
T1/2 of 1.6 hours) [3]. In our patients undergoing
CVVH, steady-state concentrations were reached by ap-
proximately 48 hours into therapy. No further drug ac-
cumulation was demonstrated after this time period.
The volume of distribution was similar to healthy volun-
teers (0.3 vs. 0.2 L/kg, respectively). The total systemic
clearance was reduced: 0.03 L/hr/kg vs. 0.11 L/hr/kg in
healthy volunteers [3]. This reduction in clearance is
expected since prescribed CVVH ultrafiltration rates
(approximately 50 ml/min) were significantly lower than
a healthy volunteer kidney with an estimated CrCl of
120 ml/min. In study patients, the SBECD clearance
correlated well with the CVVH ultrafiltration rate, and
SBECD exposure was similar to values previously ob-
served in patients with moderate renal impairment (CrCl
approximately 50 ml/min); where 4-fold increases in
AUC and a 50% increase in Cmax is observed when
compared to patients without renal dysfunction [3].
Based upon the results of our study, prescribing a predi-
lution CVVH ultrafiltration rate of at least 3,000 ml/hr
(approximately 37 ml/kg/hr) will correlate to plasma
concentrations and systemic SBECD clearance similar to
a patient with an estimated CrCl of 50 ml/min [17].
Ultrafiltration rates of 6,000 ml/hr are required to
achieve plasma SBECD exposure similar to patients
without renal dysfunction [3].
The finding that SBECD can be effectively removed
by CVVH is clinically important, because some cyclo-
dextrins have been associated with hepatotoxicity or
nephrotoxicity due to vacuolation [3]. Although our
study was small, no evidence to suggest SBECD as a
cause of hepatotoxicity or nephrotoxicity was demon-
strated in our study patients. This finding is consistent
with other SBECD safety studies in humans [3,18].
Additionally, animal studies have only been able to
Table 4 Probability of pharmacodynamic target attainment
C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis A. fumigatus A. niger A. terreus
Pfizer
4 mg/kg q12h fAUC/MIC >25 99.9 86.3 97.9 99.5 99.6 97.1
fAUC/MIC >35 99.8 81.6 94.8 99.2 99.3 92.8
6 mg/kg q12h fAUC/MIC >25 99.9 90.0 99.1 99.7 99.8 99.2
fAUC/MIC >35 99.8 86.8 98.3 99.6 99.6 97.9
EUCAST
4 mg/kg q12h fAUC/MIC >25 99.2 90.3 77.2 60.5
fAUC/MIC >35 99.1 80.3 61.9 41.6
6 mg/kg q12h fAUC/MIC >25 99.4 96.3 91.7 81.4
fAUC/MIC >35 99.2 92.1 80.3 65.4
8 mg/kg q12h fAUC/MIC >25 96.4 89.5
fAUC/MIC >35 90.6 79.0
10 mg/kg q12h fAUC/MIC >25 98.6 94.1
fAUC/MIC >35 95.4 86.1
12 mg/kg q12h fAUC/MIC >25 96.6
fAUC/MIC >35 90.6
CLSI
4 mg/kg q12h fAUC/MIC >25 99.1 89.1 94.1 99.6 98.0
fAUC/MIC >35 99.0 86.0 88.1 99.3 97.7
6 mg/kg q12h fAUC/MIC >25 99.6 92.9 98.0 99.7 98.0
fAUC/MIC >35 99.5 89.9 95.3 99.6 97.9
Data reported as % of patients obtaining target fAUC/MIC ratio at the prescribed dose. Data not available for every organism within all databases. fAUC0-12, free
area under the concentration-time curve from 0 to 12 hours; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility
Testing; CLSI, Clinical and Laboratory Standards Institute.
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more than 50-fold greater (3,000 mg/kg) than those
used in humans were administered [3,19,20]. Unlike
other cyclodextrins used in these animal studies,
SBECD undergoes only minimal tubular reabsorption
and limits concentrations within the intracellular tis-
sues of the kidney, potentially reducing the risk of
nephrotoxicity. Nevertheless, the FDA labeling for
voriconazole recommends that IV therapy be avoided,
if possible, in patients with a CrCl <50 ml/min [5]. Our
data suggest that IV voriconazole can be safely adminis-
tered in this population if the patient is concurrently
undergoing CVVH.
In our study the mean plasma voriconazole Cmax,
Cmin, T1/2, and AUC0-12 were slightly higher than
those reported in healthy volunteers receiving 4 mg/kg
IV every 12 hours. Similarly, slight alterations in volume
of distribution and clearance were also observed [7].
However, it is common for critically ill patients to dem-
onstrate altered pharmacokinetics compared to healthy
volunteers, and it is important to note that voriconazole
plasma pharmacokinetics during CVVH in our study
patients were similar to previous studies of critically illpatients [8,21]. These pharmacokinetic alterations, plus
multiorgan dysfunction in many of our patients and the
lack of patients with the poor metabolizer phenotype,
likely explains why substantial differences in pharmaco-
kinetic parameters between the different CYP2C19
phenotypes were not observed [22,23]. Although consid-
erable variability in voriconazole pharmacokinetics did
exist between patients, standard dosages of IV voricona-
zole were effective at achieving steady-state voriconazole
plasma trough levels >1 mg/L in all patients. Pharmaco-
dynamic target attainment was achieved with this dosing
strategy for the majority of pathogens within the data-
bases evaluated. These findings suggest that IV voricona-
zole 6 mg/kg IV every 12 hours for two doses followed
by 4 mg/kg IV every 12 hours provides an effective strat-
egy for the treatment of susceptible fungal pathogens in
critically ill patients. However, higher doses may be re-
quired for less susceptible pathogens including C. glab-
rata, A. niger, and A. terreus.
Contrary to SBECD, voriconazole elimination by CVVH
accounted for only a small and clinically irrelevant per-
centage (defined as a fraction of clearance due to CVVH
of <25%) of the voriconazole total body clearance.
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nal elimination and is similar to the findings of two re-
cent studies evaluating patients undergoing CRRT
while receiving IV voriconazole [8,21]. Therefore, no
dosage adjustment is required for voriconazole in pa-
tients undergoing CVVH. The voriconazole N-oxide
metabolite was readily cleared by CVVH resulting in
plasma concentrations and voriconazole/voriconazole
N-oxide concentration ratios similar to those previously
reported in patients without kidney dysfunction [13,14].
The clinical implications of these findings are yet to be
determined as the voriconazole N-oxide metabolite is
absent of antifungal activity and has not been linked to
adverse clinical effects.
Potential study limitations need to be considered when
interpreting our findings. The sample size of our study
was small. However, our study currently represents the
largest and most comprehensive study of IV voricona-
zole in patients undergoing CVVH to date. Our study
utilized only one mode and type of extracorporeal ma-
chine for delivering CRRT. Therefore, the results must
be extrapolated to institutions that use different extra-
corporeal filters, ultrafiltration rates, or post-dilution
modes. Nevertheless, it is likely based on previous stud-
ies that SBECD will be well removed by most modern
high-flux filters and dialysis modes. It is also improb-
able that voriconazole will be removed by CRRT to
an extent requiring dosage adjustment. Due to the
severity of illness and high rate of mortality in our
study, evaluation of adverse events was limited to only four
patients.
Conclusions
CVVH effectively removed SBECD at a rate similar to
the ultrafiltration rate. Voriconazole clearance by CVVH
was not clinically significant. Standard recommended
dosages of IV voriconazole are effective at achieving goal
plasma concentrations for most pathogens and can be
utilized in critically ill patients undergoing CVVH with-
out significant risk of SBECD accumulation.
Key messages
 CVVH effectively removes SBECD and allows for
the use of IV voriconazole without the risk of
SBECD accumulation
 Voriconazole removal by CVVH was minimal and
standard IV dosages were effective at maintaining
trough levels >1 mcg/ml in these critically ill
patients
 Voriconazole dosages >4 mg/kg every 12 hours may
be necessary to obtain pharmacodynamic targets for
pathogens with higher MICs, including A. niger and
A. terreusAdditional files
Additional file 1: Detailed study methodology.
Additional file 2: Figure S1. Simulated plasma SBECD pharmacokinetic
profiles for: all subjects, patients undergoing CVVH with an ultrafiltration
rate of 2,000 ml/hour, 3,000 ml/hour, and 6,000 ml/hour. Data represent
1,000 patient simulations for SBECD exposure with voriconazole 6 mg/kg
IV every 12 hours for two doses followed by 4 mg/kg IV every 12 hours
from time 0 to day 7. Data presented as mean concentration (solid lines)
and standard deviation (dashed lines).
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